Who Supplies Plasma to India from MEXICO

To import finished pharmaceutical formulations containing plasma into India, the foreign manufacturer must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves registering the manufacturing premises and the specific drug formulations. The application requires submission of a Drug Master File (DMF), Good Manufacturing Practice (GMP) certificates, and a Certificate of Pharmaceutical Product (COPP). The registration certificate is valid for three years and must be renewed before expiration. The import license, issued by the Directorate General of Foreign Trade (DGFT), is also valid for three years and is necessary for customs clearance. The entire registration and licensing process typically takes several months, depending on the completeness of the application and the efficiency of the regulatory bodies.

Imported pharmaceutical formulations containing plasma must undergo quality testing at CDSCO-approved laboratories in India. This includes batch-wise testing, where samples from each batch are analyzed for compliance with Indian Pharmacopoeia standards. The Certificate of Analysis (CoA) from the exporting country’s laboratory must accompany the shipment. Stability data, particularly for ICH Zone IV conditions, is required to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors ensures that the imported products meet all regulatory requirements before they are released into the Indian market.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical products, including formulations containing plasma. These changes aim to enhance drug safety and efficacy by ensuring that imported products meet Indian standards. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import landscape, encouraging domestic manufacturing and potentially reducing reliance on imports. Bilateral agreements between India and Mexico have facilitated smoother trade relations, but importers must stay updated on any policy changes that may affect their operations.

India imports finished pharmaceutical formulations containing plasma to meet the demand for specialized treatments not available domestically. These include patented or branded formulations and specific dosage forms that domestic manufacturers may not produce. The market size for such imports is significant, with India importing plasma formulations valued at $2.8 million across 215 exporters to 90 countries. This indicates a robust demand for these products in the Indian healthcare sector.

The import duty structure for finished pharmaceutical formulations containing plasma under HS Code 30029010 includes a 10% Basic Customs Duty, 2% Education Cess, and 1% Secondary Higher Education Cess, totaling 10.3%. Additionally, the Integrated Goods and Services Tax (IGST) is applicable at 0% for this category. Anti-dumping duties may also apply if the government determines that imports are being sold at unfairly low prices. Exemption notifications can reduce or eliminate certain duties under specific conditions, such as for products meeting certain quality standards or for use in specific sectors.

India sources finished pharmaceutical formulations containing plasma from Mexico due to several competitive advantages. Mexican manufacturers offer patented formulations and specialized dosage forms that may not be available from other suppliers. The quality of Mexican pharmaceutical products is generally high, adhering to international standards. While other countries like China, Germany, and the United States also supply similar products, Mexico's unique offerings and quality standards make it a preferred source for certain formulations.

India imports finished pharmaceutical formulations containing plasma from Mexico due to the availability of patented formulations and specialized dosage forms not produced domestically. Mexican manufacturers offer high-quality products that meet international standards, fulfilling specific treatment needs in India. The importation of these formulations is strategic to address gaps in domestic production and to provide patients with access to essential therapies.

When compared to other origins like China, the European Union, and the United States, Mexico offers competitive advantages in terms of product quality and regulatory compliance. Mexican pharmaceutical products adhere to international standards, ensuring reliability and safety. While other countries may offer lower prices, Mexico's consistent quality and adherence to regulatory standards make it a preferred choice for certain formulations.

Importers face several risks when sourcing finished pharmaceutical formulations containing plasma from Mexico. These include single-source dependency, currency fluctuations, potential regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory developments, implement stringent quality assurance processes, and develop contingency plans for shipping disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs to ensure cost-effectiveness and flexibility.
5. 5Supplier Qualification: Conduct thorough due diligence to assess supplier reliability and compliance with quality standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the manufacturing premises and the specific drug